Towards equitable AI in oncology

Nature Reviews Clinical Oncology, Год журнала: 2024, Номер 21(8), С. 628 - 637

Опубликована: Июнь 7, 2024

Язык: Английский

---

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Янв. 12, 2025

Abstract This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) enrolled. Eligible Patients randomly assigned (1:1) to receive four cycles (21 days as one cycle) of intravenous carboplatin (area under the curve 5 mg/mL per min, day 1 each etoposide (100 mg/m² body-surface area, on 1–3 with either socazolimab (5 mg/kg, or matching placebo, following maintenance therapy placebo. From July 15, 2021, May 12, 2022, 498 eligible patients (250 patients) placebo (248 combined chemotherapy. As October 13, 2023, presented significant overall survival (OS) benefit (13.90 months) compared plus EC group (11.58 (hazard ratio death, 0.799; 95% CI, 0.652–0.979; p = 0.0158). The median progression free (PFS) was 5.55 months group, prolonging disease death by nearly 1.2 (5.55 vs 4.37 months, hazard 0.569; 0.457–0.708; < 0.0001). 200 (80.3%) experienced ≥ grade treatment-related adverse events 187 (75.7%) occurred group. Socazolimab standard regimen chemotherapy first-line treatment ES-SCLC significantly prolonged did not increase safety risk treatment.

Язык: Английский

---

Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database

Journal of Cancer Research and Clinical Oncology, Год журнала: 2025, Номер 151(2)

Опубликована: Фев. 8, 2025

In recent years, due to various risk factors, the incidence, prevalence, and mortality rates of female lung cancer have been increasing in both China globally. This has become a significant public health challenge worldwide. Lung not only poses severe threat women's but also places heavy burden on families society. To conduct an in-depth analysis trends disease for globally from 1990 2021 forecast next 15 years (2022–2037). The aim is provide reliable theoretical basis reference value clinical research practice offer guidance resource allocation policy-making Based Global Burden Disease (GBD) database, we analyzed mortality, disability-adjusted life (DALYs) 2021. These metrics were stratified by gender (BOTH, MALE, FEMALE), average annual percentage change (AAPC) was calculated each metric over this period. JOINPOINT regression model used analyze ARIMA applied changes age-standardized incidence (ASIR) (ASDR) fifteen (2022–2037) results indicate upward trend DALYs China. Globally, prevalence showed trend, while demonstrated declining trend. Both globally, DALY higher than those males. From 2021, exhibited with AAPC growth 1.151%, 2.086%, 0.508%, 0.210%, respectively. Similarly, 0.576%, 1.123%, 0.276%, respectively, slight decline -0.029%. Although overall as high that males, rate significantly males are global average.

Язык: Английский

---

Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds

Pharmaceuticals, Год журнала: 2025, Номер 18(2), С. 270 - 270

Опубликована: Фев. 19, 2025

Background: Despite recent breakthroughs in cancer treatment, non-small cell lung (NSCLC) and breast remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an important mediator the pathways involved proliferation, apoptosis, angiogenesis. Thus, its overexpression triggers several types cancer, including NSCLC cancer. Methods: In current study, we synthesized new pyrimidine-tethered compounds (chalcone derivative (B-4), pyrazoline-carbothioamide (B-9), pyrazoline-thiazole hybrids (BH1-7)). These were then tested for cytotoxicity against A549 MCF-7 cells. Results: Of these, B-4 displayed significant both cells (IC50 = 6.70 ± 1.02 µM MCF-7; IC50 20.49 2.7 A549) compared to standard agent lapatinib 9.71 1.12 18.21 3.25 A549). anticancer potential between Jurkat leukemic T peripheral blood mononuclear (PBMCs) (healthy) was found be selective. Mechanistically, 11.9% 10.2% treated with B-4, respectively, underwent apoptosis produced 46% EGFR inhibition at a concentration 10 μM. B-4/EGFR complex obtained after induced fit docking subjected 300 ns molecular dynamics simulation, which confirmed stability mimicked biological environment. On other hand, shown have drug-like properties by silico pharmacokinetic estimation. Conclusions: inhibitor inducer future studies.

Язык: Английский

---

Lifestyle, Environmental, Occupational, and Dietary Risk Factors in Small-Cell vs. Non-Small-Cell Advanced Lung Cancer Patients: Is There a Connection?

Cancers, Год журнала: 2025, Номер 17(5), С. 864 - 864

Опубликована: Март 3, 2025

(i) To evaluate the possible exposure of newly diagnosed lung cancer patients to selected lifestyle, environmental, occupational, and dietary risk factors (ii) assess differences in exposures small-cell (SCLC) non-small-cell (NSCLC) those factors. In this study, 205 with IIIB/IV stage either SCLC or NSCLC (111 men vs. 94 women) from Vojvodina, Serbia, were surveyed for demographic characteristics, lifestyle habits, environmental Most long-term heavy smokers. The body mass index values higher than patients. Women reported stress levels compared men. adenocarcinoma more often exposed traffic pollution Individual indoor coal combustion systems used by both sexes other types. Men frequent consumers canned foods, which are potential sources endocrine disruptors. Occupational factors, addition tobacco smoking, may be crucial development specific occupations. Further research on occupational is urgent order unveil etiopathogenesis

Язык: Английский

---

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Cancer Treatment Reviews, Год журнала: 2024, Номер 131, С. 102845 - 102845

Опубликована: Окт. 16, 2024

Язык: Английский

---

Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study

Lung Cancer, Год журнала: 2025, Номер 202, С. 108485 - 108485

Опубликована: Март 7, 2025

Язык: Английский

---

Current insights into the clinico-pathologic characteristics of lung cancer in women

Expert Review of Respiratory Medicine, Год журнала: 2025, Номер unknown, С. 1 - 12

Опубликована: Март 5, 2025

Lung cancer is responsible for premature deaths in women and the first cause of many countries. The problem lung seems to be underestimated aspects, including low participation clinical trials screening tests. Current research progress has contributed a better understanding issue makes it possible describe new light. In our paper, was discussed broad aspect, taking into account women's health, harmful effects smoking current diagnostic treatment process. results also differ relation sex. All these aspects diversity were presented on basis newest most comprehensive literature. will remain an important health worldwide, which justified by epidemiological data, basic results.

Язык: Английский

---

Medicaid Expansion is Associated with Differences in Local Therapy for Non-small Cell Lung Cancer

Annals of Surgical Oncology, Год журнала: 2025, Номер unknown

Опубликована: Март 5, 2025

Язык: Английский

---

Optimizing pulmonary nodule segmentation in CT imaging: A comparative study of anchor-based and anchor-free detectors using attention mechanism

Multimedia Tools and Applications, Год журнала: 2025, Номер unknown

Опубликована: Март 18, 2025

Язык: Английский

---